NYSE:ZYME

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. More Details


Snowflake Analysis

Flawless balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Zymeworks's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZYME is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ZYME's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-2.1%

ZYME

4.5%

US Biotechs

0.3%

US Market


1 Year Return

10.8%

ZYME

40.6%

US Biotechs

21.1%

US Market

Return vs Industry: ZYME underperformed the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: ZYME underperformed the US Market which returned 19.5% over the past year.


Shareholder returns

ZYMEIndustryMarket
7 Day-2.1%4.5%0.3%
30 Day2.7%6.8%3.3%
90 Day30.0%27.2%14.2%
1 Year10.8%10.8%42.9%40.6%23.8%21.1%
3 Year346.3%346.3%28.8%22.1%45.0%35.4%
5 Yearn/a51.3%39.6%127.7%102.3%

Long-Term Price Volatility Vs. Market

How volatile is Zymeworks's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zymeworks undervalued compared to its fair value and its price relative to the market?

5.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ZYME's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZYME is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ZYME is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZYME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZYME is overvalued based on its PB Ratio (5.6x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Zymeworks forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-7.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYME's revenue (45.5% per year) is forecast to grow faster than the US market (10.3% per year).

High Growth Revenue: ZYME's revenue (45.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZYME's Return on Equity is forecast to be very high in 3 years time (99.3%).


Next Steps

Past Performance

How has Zymeworks performed over the past 5 years?

-51.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZYME is currently unprofitable.

Growing Profit Margin: ZYME is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZYME is unprofitable, and losses have increased over the past 5 years at a rate of 51.3% per year.

Accelerating Growth: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: ZYME has a negative Return on Equity (-49.71%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zymeworks's financial position?


Financial Position Analysis

Short Term Liabilities: ZYME's short term assets ($487.3M) exceed its short term liabilities ($96.9M).

Long Term Liabilities: ZYME's short term assets ($487.3M) exceed its long term liabilities ($42.5M).


Debt to Equity History and Analysis

Debt Level: ZYME is debt free.

Reducing Debt: ZYME had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZYME has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ZYME has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 33.1% each year.


Next Steps

Dividend

What is Zymeworks's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZYME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZYME's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Ali Tehrani (48 yo)

no data

Tenure

US$3,278,069

Compensation

Dr. Ali Tehrani, Ph.D. is a Co-Founder of Zymeworks, Inc. and serves as its Chief Executive Officer and President. Dr. Tehrani has been an integral part of many of Zymeworks' corporate achievements, includ...


CEO Compensation Analysis

Compensation vs Market: Ali's total compensation ($USD3.28M) is below average for companies of similar size in the US market ($USD5.00M).

Compensation vs Earnings: Ali's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ali Tehrani
Co-Founderno dataUS$3.28m0.68%
$ 16.5m
Anthony Polverino
Chief Scientific Officer & Executive VP of Early Development2.33yrsUS$1.34m0.064%
$ 1.6m
Kathryn O'Driscoll
Chief People Officer1.25yrsUS$2.39m0.0064%
$ 154.5k
Diana Hausman
Chief Medical Officer4.58yrsUS$1.40m0.013%
$ 313.3k
Neil Josephson
Senior Vice President of Clinical Research1yrUS$1.62mno data
Neil Klompas
Executive VP of Business Operations & CFOno dataUS$1.05m0.022%
$ 533.6k
Surjit Dixit
Vice President of Technologyno dataUS$497.90kno data
Daniel Dex
VP of Legal & Corporate Secretaryno datano datano data
John Babcook
Senior Vice President of Discovery Research4.83yrsUS$400.71kno data
Mark Hollywood
Senior Vice President of Technical & Manufacturing Operations1.83yrsno datano data
Bruce Hart
Senior Vice President of Regulatory1yrno datano data
James Daniel Priour
Senior Vice President of Commercial0.75yrno datano data

1.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: ZYME's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ali Tehrani
Co-Founderno dataUS$3.28m0.68%
$ 16.5m
Hollings Renton
Independent Director3.92yrsUS$172.16kno data
Lota Zoth
Independent Chair of the Board of Directors1.33yrsUS$184.19kno data
Kenneth Hillan
Independent Director3.92yrsUS$107.79kno data
Kelvin Neu
Independent Director0.83yrno datano data
Susan Mahony
Independent Director1.58yrsUS$392.85kno data
Natalie Sacks
Independent Director3.42yrsUS$160.61kno data
Troy Cox
Independent Director1.58yrsUS$392.48k0.016%
$ 396.4k

2.5yrs

Average Tenure

56yo

Average Age

Experienced Board: ZYME's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ZYME insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.5%.


Top Shareholders

Company Information

Zymeworks Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zymeworks Inc.
  • Ticker: ZYME
  • Exchange: NYSE
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.429b
  • Shares outstanding: 45.95m
  • Website: https://www.zymeworks.com

Number of Employees


Location

  • Zymeworks Inc.
  • 1385 West 8th Avenue
  • Suite 540
  • Vancouver
  • British Columbia
  • V6H 3V9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZYMENYSE (New York Stock Exchange)YesCommon SharesUSUSDApr 2017
ZYMETSX (The Toronto Stock Exchange)YesCommon SharesCACADApr 2017
0OXDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2017

Biography

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company’s lead product candidat...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/19 23:25
End of Day Share Price2021/01/19 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.